NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 recruiting NCT06090162
LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma No drug interventions diagnostic Not Available recruiting NCT06028373
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT05685173
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT03588598
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies No drug interventions treatment 1 unknown_status NCT04696432
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma treatment 1 active_not_recruiting NCT04693676
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma treatment 1 active_not_recruiting NCT02361346
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL No drug interventions treatment 1 / 2 terminated NCT02715843
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma No drug interventions Not Available Not Available no_longer_available NCT04655677
A Study of EXP039 Treatment in Subjects With r/r NHL Subjects No drug interventions treatment 1 unknown_status NCT04317885
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects No drug interventions treatment 1 active_not_recruiting NCT04148742
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) No drug interventions treatment 1 / 2 suspended NCT03000192
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life No drug interventions Not Available Not Available unknown_status NCT01994382
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL No drug interventions treatment 1 / 2 completed NCT02456207
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 2 unknown_status NCT02787239
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL No drug interventions treatment 3 completed NCT02584920
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma No drug interventions treatment 1 / 2 completed NCT02206308
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. No drug interventions treatment 1 completed NCT05097443
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma treatment 3 recruiting NCT04923048
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. No drug interventions treatment 1 / 2 recruiting NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT04088890
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies No drug interventions treatment 1 active_not_recruiting NCT06365671
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors treatment 2 recruiting NCT05779930
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL No drug interventions treatment 0 not_yet_recruiting NCT05094206
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies No drug interventions treatment 1 active_not_recruiting NCT04748185
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies No drug interventions Not Available Not Available completed NCT04191941
Treatment of Hematological Malignancy With Novel CAR-T Cells. No drug interventions treatment 0 unknown_status NCT04148430
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy treatment 2 active_not_recruiting NCT05702853
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL treatment 1 / 2 recruiting NCT05744037
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells No drug interventions treatment 2 recruiting NCT03283137
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL treatment 1 active_not_recruiting NCT04296461
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 unknown_status NCT06526793
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL No drug interventions treatment 2 not_yet_recruiting NCT04257578
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma treatment 1 / 2 recruiting NCT06464185
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT06497452
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Not Available Not Available recruiting NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT03671018
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma treatment 1 / 2 active_not_recruiting NCT05432635
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT02847130
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology No drug interventions Not Available Not Available completed NCT05201248
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma treatment 1 / 2 active_not_recruiting NCT06508775
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies No drug interventions other Not Available recruiting NCT06392477
A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT06027957
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia No drug interventions treatment 1 recruiting NCT05991388
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 / 3 active_not_recruiting NCT05164770
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma No drug interventions treatment 3 recruiting NCT04594642
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04544592
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL No drug interventions treatment 1 / 2 recruiting NCT03870945
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) treatment 1 / 2 completed NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL treatment 1 / 2 completed NCT03778073
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma treatment 1 terminated NCT05667155
Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04412174
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL No drug interventions treatment 0 unknown_status NCT03114865
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance treatment 1 / 2 active_not_recruiting NCT03505762
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment treatment 2 active_not_recruiting NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) treatment 1 recruiting NCT00992446
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma treatment 2 completed NCT03704714
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma treatment 1 / 2 suspended NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies treatment 1 / 2 not_yet_recruiting NCT02151903
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL No drug interventions treatment 1 / 2 terminated NCT04359784
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy prevention 2 recruiting NCT06191887
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies treatment 1 recruiting NCT02633111
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas No drug interventions Not Available Not Available active_not_recruiting NCT05053971
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas No drug interventions treatment 1 / 2 recruiting NCT03483688
A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects No drug interventions treatment 1 completed NCT01874288
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL No drug interventions treatment 1 / 2 terminated NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies No drug interventions treatment 1 terminated NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies No drug interventions treatment 1 completed NCT05927558
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study No drug interventions Not Available Not Available recruiting NCT05472558
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL No drug interventions treatment 1 recruiting NCT04887012
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL No drug interventions treatment 1 unknown_status NCT04836195
Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma No drug interventions treatment 1 recruiting NCT05338931
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 / 2 recruiting NCT02910063
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL No drug interventions treatment 2 / 3 completed NCT01516580
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients No drug interventions treatment 3 unknown_status NCT01919619
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies No drug interventions treatment 1 completed NCT03677141
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT06242834
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT06052826
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study No drug interventions supportive_care 2 recruiting NCT03017820
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma No drug interventions treatment 1 recruiting NCT06251180
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 active_not_recruiting NCT02424968
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma No drug interventions treatment 2 completed NCT03195010
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia No drug interventions supportive_care 2 terminated NCT02928510
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma No drug interventions Not Available Not Available terminated NCT02981914
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation No drug interventions treatment 0 completed NCT06446128
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) No drug interventions treatment 0 active_not_recruiting NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). No drug interventions treatment 1 / 2 recruiting NCT06008691
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice No drug interventions Not Available Not Available recruiting NCT06318884
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 not_yet_recruiting NCT02772198
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies No drug interventions treatment 1 / 2 unknown_status NCT06534437
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) No drug interventions treatment 2 not_yet_recruiting NCT05397496
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT03888105
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies No drug interventions treatment 2 recruiting NCT06230224
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma No drug interventions treatment 3 recruiting NCT05607420
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT00421395
Safety Study of NHL With 90Y-hLL2 IgG treatment 1 / 2 completed NCT05869279
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 recruiting NCT05312801
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT05619367
A Compassionate Use (CU) Program of Odronextamab Not Available Not Available available NCT02920697
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT04049513
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) treatment 1 active_not_recruiting NCT06561425
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT03244176
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study treatment 0 active_not_recruiting NCT06539338
Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment No drug interventions treatment 1 recruiting NCT03029338
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma No drug interventions treatment 1 completed NCT03379493
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells No drug interventions Not Available Not Available recruiting NCT05968001
Obinutuzumab in Chinese Real-world Patients With iNHL No drug interventions Not Available Not Available not_yet_recruiting NCT03488251
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma treatment 2 terminated NCT05518383
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 treatment 4 recruiting NCT05050461
Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma No drug interventions health_services_research Not Available unknown_status NCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction treatment 2 not_yet_recruiting NCT05741359
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04094142
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma treatment 2 completed NCT03720496
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy No drug interventions treatment 1 unknown_status NCT06156774
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project No drug interventions Not Available Not Available recruiting NCT04661020
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 2 recruiting NCT04532268
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL No drug interventions treatment 0 recruiting NCT04435743
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas Not Available Not Available unknown_status NCT03497533
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 No drug interventions treatment 1 / 2 unknown_status NCT04897477
Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma treatment 1 / 2 unknown_status NCT02081937
CART-19 Immunotherapy in Mantle Cell Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 not_yet_recruiting NCT06160362
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment Not Available recruiting NCT06321289
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL No drug interventions treatment 1 / 2 recruiting NCT05631912
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL No drug interventions treatment 1 / 2 recruiting NCT06346912
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL No drug interventions treatment 0 recruiting NCT05143112
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT02924402
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies treatment 1 active_not_recruiting NCT05513612
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies treatment 1 withdrawn NCT01351935
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia treatment 1 completed NCT04637763
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) treatment 1 recruiting NCT03417414
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? No drug interventions Not Available Not Available unknown_status NCT05149391
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 recruiting NCT04697290
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. No drug interventions treatment 0 suspended NCT05332054
Long-Term Follow-up Study No drug interventions Not Available Not Available enrolling_by_invitation NCT06104553
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma No drug interventions treatment 1 / 2 recruiting NCT00927797
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) treatment 2 unknown_status NCT05771883
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide treatment 1 / 2 not_yet_recruiting NCT06314828
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL No drug interventions treatment 1 not_yet_recruiting NCT05091541
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma treatment 1 / 2 not_yet_recruiting NCT03105596
Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) treatment 2 unknown_status NCT02564744
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL treatment 2 completed NCT05453669
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL No drug interventions treatment 1 recruiting NCT01352312
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma treatment 1 terminated NCT03639181
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) treatment 2 unknown_status NCT00457782
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT04746131
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) No drug interventions treatment 1 suspended NCT00588094
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL No drug interventions treatment 2 completed NCT05190068
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 recruiting NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 2 recruiting